more

AbbVie (ABBV)

(Real Time Quote from BATS)

$193.24 USD

-2.21 (-1.13%)

Updated Oct 4, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research Published on April 28,2022

Sector ETF report for FXH

Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates?

by Zacks Equity Research Published on April 27,2022

Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.

biotechs

Universal Health (UHS) Q1 Earnings Miss Mark, Tumble Y/Y

by Zacks Equity Research Published on April 26,2022

Universal Health's (UHS) Q1 results reflect a steep expense level and lower admissions in its Behavioral Health Care Services segment, partially offset by revenue recognition.

Healthcare ETFs in Focus Ahead of Q1 Earnings

by Sweta Killa Published on April 26,2022

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.

etfs
medical

Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research Published on April 26,2022

AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.

pharmaceuticals

Will Merck (MRK) Beat Expectations This Earnings Season?

by Zacks Equity Research Published on April 26,2022

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.

pharmaceuticals

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research Published on April 25,2022

AbbVie (ABBV) closed at $156.30 in the latest trading session, marking a +0.85% move from the prior day.

ABBVNegative Net Change

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research Published on April 22,2022

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABBVNegative Net Change